NEWS - Aug 9, 2022 Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder Read more
NEWS - Aug 5, 2022 Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022 Read more
NEWS - Jul 21, 2022 Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial Read more
NEWS - Jun 7, 2022 Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference Read more
NEWS - Jun 2, 2022 Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference Read more
NEWS - May 25, 2022 Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting Read more
NEWS - May 5, 2022 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results Read more
NEWS - Apr 29, 2022 Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology Read more
NEWS - Apr 28, 2022 Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022 Read more
NEWS - Apr 4, 2022 Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022 Read more
